【財華社訊】科濟藥業-B(02171.HK)公佈，CT0590(一種靶向BCMA的同種異體CAR-T細胞候選產品)、CT071(一種靶向G蛋白偶聯受體C組5成員D(GPRC5D)的自體CAR-T細胞候選產品)和賽愷澤(澤沃基奧侖賽注射液，產品編號：CT053，一種靶向BCMA的自體CAR-T細胞產品)的更新結果已在第66屆美國血液學會(「ASH」)年會上進行報告。
科濟藥業-B(02171.HK)於2024年ASH年會呈列賽愷澤、CT071和CT0590研究成果更新
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated